A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Inclusion Criteria

• •Inclusion:
• •Subject must have a histologically or cytologically confirmed metastatic or locally advanced solid tumor which is progressing.
• •Subject must have documented KRAS p.G12C mutation identified within the last 5 years by a local test on tumor tissue or blood.
• •Subject must have measurable disease per RECIST v1.1.
• •Subject must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• •Subject must have adequate organ and marrow function within the screening period.
• •Exclusion:
• •Subject has any prior treatment with other treatments without adequate washout periods as defined in the protocol.
• •Subject has uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, uncontrolled or significant cardiovascular disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirements, substantially increase risk of incurring AEs, or compromise the ability of the subject to give written informed consent.
• •Subject has unresolved treatment-related toxicities from previous anticancer therapy of NCI CTCAE Grade ≥2 (with exception of vitiligo or alopecia).
• +2 more criteria